glp-1 clinical trials Obesity GLP-1 Drug Pipeline 2026 |
Description
The exciting beyond obesity frontier for GLP-1 drugs is their potential to treat conditions where inflammation, or other non-obesity factors, are the primary cause
Regular monitoring is essential to assess treatment efficacy and adjust therapy as needed
J., & Tiwari, B
2020, p
